Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07679750 · ClinicalTrials.gov registry record · NA
rTMS Device for Improvement of Obsessive and Compulsive Behaviors
A NA study, sponsored by BTL Industries.
- Not yet
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT07679750 is a NA study that has not yet begun recruiting, run by BTL Industries. The registered enrollment target is 60 participants.
The verdict
NCT07679750, a NA study, has not yet begun recruiting, sponsored by BTL Industries.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this investigational study is to evaluate if the treatment using EXOMIND(BTL-699-2) device is able to improve severity of obsessive and compulsive symptoms in adults (aged 22 and older). The main question it aims to answer is: Does the treatment using EXOMIND (BTL-699-2) device is able safely and efficiently reduce the severity of obsessive and compulsive behaviors? Participants will be asked to: * Complete six treatment visits (twelve treatment sessions) * Complete The Yale-Brown Obsessive-Compulsive Severity Scale Second Edition Self Report Version (Y-BOCS-II SR) * Complete Short UPPS-P Impulsive Behaviour Scale (SUPPS-P) * Compete The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) * Compete The Patient Health Questionnaire-9 (PHQ-9) * Compete Columbia Suicide Severity Rating Scale -screen version(CSSRS) * Complete Trigger Recall Experience Questionnaire (only for participants who agree to participate in trigger recall procedure during the treatment sessions) * Compete The Therapy Comfort Questionnaire * Compete The Subject Satisfaction Questionnaire
Interventions
- DEVICE EXOMIND (BTL-699-2) Active treatment
- DEVICE EXOMIND (BTL-699-2) Sham treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06-24 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07679750
The ClinicalTrials.gov registry entry for NCT07679750 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BTL Industries, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EXOMIND (BTL-699-2) Active treatment is the first listed.
NCT07679750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07679750 about?
NCT07679750 is a clinical study titled "rTMS Device for Improvement of Obsessive and Compulsive Behaviors". The goal of this investigational study is to evaluate if the treatment using EXOMIND(BTL-699-2) device is able to improve severity of obsessive and compulsive symptoms in adults (aged 22 and older). The main question it aims to answer is: Does the treatment using EXOMIND (BTL-699-2) device is able...
What is the current status of trial NCT07679750?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2026-06-24. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07679750?
The interventions under investigation include: EXOMIND (BTL-699-2) Active treatment (DEVICE), EXOMIND (BTL-699-2) Sham treatment (DEVICE).
Who is sponsoring clinical trial NCT07679750?
This trial is sponsored by BTL Industries, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.